Oppenheimer Reiterates Outperform Rating on Ligand Pharma (LGND)

September 24, 2026 9:54 AM

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $334.00 price target on Ligand Pharma (NASDAQ: LGND).The analyst commented: "Ligand ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found